Trade DiaMedica Therapeutics Inc. - DMAC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0854 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 1.4477 |
| Open* | 1.3882 |
| 1-Year Change* | -42.87% |
| Day's Range* | 1.3686 - 1.4872 |
| 52 wk Range | 1.12-2.71 |
| Average Volume (10 days) | 23.15K |
| Average Volume (3 months) | 743.65K |
| Market Cap | 38.87M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 26.46M |
| Revenue | N/A |
| EPS | -0.52 |
| Dividend (Yield %) | N/A |
| Beta | 1.75 |
| Next Earnings Date | May 3, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 30, 2023 | 1.4477 | 0.0301 | 2.12% | 1.4176 | 1.5262 | 1.3880 |
| Mar 29, 2023 | 1.4382 | -0.0478 | -3.22% | 1.4860 | 1.5061 | 1.3688 |
| Mar 28, 2023 | 1.4869 | -0.0281 | -1.85% | 1.5150 | 1.5947 | 1.4763 |
| Mar 27, 2023 | 1.4573 | 0.0693 | 4.99% | 1.3880 | 1.5068 | 1.3880 |
| Mar 24, 2023 | 1.5261 | 0.1576 | 11.52% | 1.3685 | 1.5261 | 1.3684 |
| Mar 23, 2023 | 1.4380 | -0.1068 | -6.91% | 1.5448 | 1.5751 | 1.4380 |
| Mar 22, 2023 | 1.5458 | -0.0479 | -3.01% | 1.5937 | 1.6633 | 1.5454 |
| Mar 21, 2023 | 1.6729 | -0.0391 | -2.28% | 1.7120 | 1.7122 | 1.5843 |
| Mar 20, 2023 | 1.6925 | -0.0382 | -2.21% | 1.7307 | 1.7314 | 1.6529 |
| Mar 17, 2023 | 1.7316 | -0.0188 | -1.07% | 1.7504 | 1.7505 | 1.7010 |
| Mar 16, 2023 | 1.8296 | 0.0891 | 5.12% | 1.7405 | 1.8394 | 1.7405 |
| Mar 15, 2023 | 1.6923 | -0.0383 | -2.21% | 1.7306 | 1.7416 | 1.6820 |
| Mar 14, 2023 | 1.7805 | 0.0878 | 5.19% | 1.6927 | 1.8297 | 1.6422 |
| Mar 13, 2023 | 1.6922 | 0.1276 | 8.16% | 1.5646 | 1.7221 | 1.5646 |
| Mar 10, 2023 | 1.6531 | -0.0182 | -1.09% | 1.6713 | 1.7019 | 1.5645 |
| Mar 9, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7707 | 1.6421 |
| Mar 8, 2023 | 1.7709 | 0.0994 | 5.95% | 1.6715 | 1.7906 | 1.6715 |
| Mar 7, 2023 | 1.7219 | 0.0798 | 4.86% | 1.6421 | 1.7221 | 1.6421 |
| Mar 6, 2023 | 1.7020 | -0.0188 | -1.09% | 1.7208 | 1.7612 | 1.6723 |
| Mar 3, 2023 | 1.7316 | 0.0790 | 4.78% | 1.6526 | 1.7514 | 1.6526 |
DiaMedica Therapeutics Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0.5 | 0 |
| Total Operating Expense | 13.646 | 12.699 | 11.593 | 7.261 | 4.519 |
| Selling/General/Admin. Expenses, Total | 4.881 | 4.389 | 3.693 | 2.739 | 1.313 |
| Research & Development | 8.765 | 8.31 | 7.9 | 4.522 | 3.206 |
| Depreciation / Amortization | |||||
| Operating Income | -13.646 | -12.699 | -11.593 | -6.761 | -4.519 |
| Interest Income (Expense), Net Non-Operating | 0 | -0.039 | 0.009 | ||
| Other, Net | 0.082 | 0.434 | 0.975 | 1.146 | 0.25 |
| Net Income Before Taxes | -13.564 | -12.265 | -10.618 | -5.654 | -4.26 |
| Net Income After Taxes | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Net Income Before Extra. Items | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Net Income | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Income Available to Common Excl. Extra. Items | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Income Available to Common Incl. Extra. Items | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Diluted Net Income | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Diluted Weighted Average Shares | 20.7734 | 15.6803 | 11.9877 | 7.74352 | 5.93579 |
| Diluted EPS Excluding Extraordinary Items | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
| Diluted Normalized EPS | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
| Revenue | 0 | 0.5 | 0 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 3.128 | 3.364 | 3.536 | 3.246 | 3.416 |
| Selling/General/Admin. Expenses, Total | 1.488 | 1.409 | 1.562 | 1.375 | 1.084 |
| Research & Development | 1.64 | 1.955 | 1.974 | 1.871 | 2.332 |
| Operating Income | -3.128 | -3.364 | -3.536 | -3.246 | -3.416 |
| Other, Net | 0.076 | 0.013 | 0.035 | 0.007 | -0.027 |
| Net Income Before Taxes | -3.052 | -3.351 | -3.501 | -3.239 | -3.443 |
| Net Income After Taxes | -3.059 | -3.358 | -3.508 | -3.246 | -3.45 |
| Net Income Before Extra. Items | -3.059 | -3.358 | -3.508 | -3.246 | -3.45 |
| Net Income | -3.059 | -3.358 | -3.508 | -3.246 | -3.45 |
| Income Available to Common Excl. Extra. Items | -3.059 | -3.358 | -3.508 | -3.246 | -3.45 |
| Income Available to Common Incl. Extra. Items | -3.059 | -3.358 | -3.508 | -3.246 | -3.45 |
| Diluted Net Income | -3.059 | -3.358 | -3.508 | -3.246 | -3.45 |
| Diluted Weighted Average Shares | 26.4431 | 26.4431 | 26.4431 | 26.5021 | 19.0357 |
| Diluted EPS Excluding Extraordinary Items | -0.11568 | -0.12699 | -0.13266 | -0.12248 | -0.18124 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.11568 | -0.12699 | -0.13266 | -0.12248 | -0.18124 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 45.439 | 27.921 | 8.836 | 17.972 | 1.494 |
| Cash and Short Term Investments | 45.112 | 27.507 | 7.878 | 16.823 | 1.353 |
| Cash | 4.707 | 7.409 | 3.883 | 16.823 | 1.353 |
| Total Receivables, Net | 0.13 | 0.34 | 0.823 | 0.78 | 0.08 |
| Prepaid Expenses | 0.084 | 0.064 | 0.047 | 0.369 | 0.061 |
| Total Assets | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
| Property/Plant/Equipment, Total - Net | 0.112 | 0.174 | 0.217 | 0.096 | 0.037 |
| Property/Plant/Equipment, Total - Gross | 0.179 | 0.231 | 0.26 | ||
| Accumulated Depreciation, Total | -0.067 | -0.057 | -0.043 | ||
| Total Current Liabilities | 1.524 | 2.028 | 1.318 | 1.296 | 1.003 |
| Accounts Payable | 0.509 | 1.099 | 0.182 | ||
| Accrued Expenses | 1.011 | 0.923 | 1.13 | ||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.084 | |||
| Total Liabilities | 1.527 | 2.081 | 1.436 | 1.314 | 1.003 |
| Total Long Term Debt | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
| Other Liabilities, Total | 0 | 0.046 | 0.105 | ||
| Total Equity | 44.024 | 26.014 | 7.617 | 17.025 | 0.799 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 126.576 | 94.925 | 64.232 | 62.993 | 41.033 |
| Retained Earnings (Accumulated Deficit) | -82.501 | -68.909 | -56.617 | -45.968 | -40.234 |
| Other Equity, Total | -0.051 | -0.002 | 0.002 | ||
| Total Liabilities & Shareholders’ Equity | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
| Total Common Shares Outstanding | 26.4431 | 18.7462 | 12.0069 | 11.9569 | 6.37066 |
| Accounts Receivable - Trade, Net | 0.13 | 0.78 | 0.08 | ||
| Other Long Term Assets, Total | 0 | 0.271 | 0.271 | ||
| Payable/Accrued | 1.291 | 0.919 | |||
| Current Port. of LT Debt/Capital Leases | 0.004 | 0.006 | 0.006 | 0.005 | 0 |
| Capital Lease Obligations | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
| Short Term Investments | 40.405 | 20.098 | 3.995 | ||
| Other Current Assets, Total | 0.113 | 0.01 | 0.088 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 42.111 | 45.439 | 48.537 | 21.629 | 24.195 |
| Cash and Short Term Investments | 41.047 | 45.112 | 48.097 | 21.295 | 23.401 |
| Cash | 3.032 | 4.707 | 16.219 | 2.228 | 3.329 |
| Short Term Investments | 38.015 | 40.405 | 31.878 | 19.067 | 20.072 |
| Total Receivables, Net | 0.168 | 0.13 | 0.104 | 0.016 | 0.337 |
| Prepaid Expenses | 0.793 | 0.084 | 0.336 | 0.318 | 0.457 |
| Total Assets | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
| Property/Plant/Equipment, Total - Net | 0.1 | 0.112 | 0.127 | 0.145 | 0.161 |
| Property/Plant/Equipment, Total - Gross | 0.162 | 0.179 | 0.187 | 0.199 | 0.209 |
| Accumulated Depreciation, Total | -0.062 | -0.067 | -0.06 | -0.054 | -0.048 |
| Total Current Liabilities | 1.434 | 1.524 | 1.624 | 1.44 | 1.178 |
| Accounts Payable | 0.433 | 0.509 | 0.699 | 0.239 | 0.689 |
| Accrued Expenses | 0.995 | 1.011 | 0.921 | 1.196 | 0.483 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.006 | 0.004 | 0.004 | 0.005 | 0.006 |
| Total Liabilities | 1.443 | 1.527 | 1.628 | 1.456 | 1.211 |
| Total Long Term Debt | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
| Capital Lease Obligations | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
| Other Liabilities, Total | 0 | 0 | 0.011 | 0.028 | |
| Total Equity | 40.768 | 44.024 | 47.036 | 20.318 | 23.145 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 126.884 | 126.576 | 126.296 | 96.126 | 95.68 |
| Retained Earnings (Accumulated Deficit) | -86.009 | -82.501 | -79.255 | -75.805 | -72.531 |
| Other Equity, Total | -0.107 | -0.051 | -0.005 | -0.003 | -0.004 |
| Total Liabilities & Shareholders’ Equity | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
| Total Common Shares Outstanding | 26.4431 | 26.4431 | 26.4392 | 18.7862 | 18.7862 |
| Accounts Receivable - Trade, Net | 0.166 | 0.13 | |||
| Other Current Assets, Total | 0.103 | 0.113 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Cash From Operating Activities | -12.252 | -9.185 | -9.102 | -5.696 | -3.9 |
| Cash From Operating Activities | 0.024 | 0.021 | 0.021 | 0.015 | 0.004 |
| Non-Cash Items | 1.777 | 1.891 | 1.139 | 0.659 | 0.4 |
| Cash Interest Paid | 0.002 | 0.002 | |||
| Changes in Working Capital | -0.461 | 1.195 | 0.387 | -0.636 | -0.044 |
| Cash From Investing Activities | -20.537 | -16.134 | -3.908 | -0.05 | -0.022 |
| Capital Expenditures | -0.022 | -0.047 | -0.002 | -0.05 | -0.022 |
| Cash From Financing Activities | 30.087 | 28.845 | 0.07 | 21.216 | 3.539 |
| Issuance (Retirement) of Stock, Net | 30.093 | 28.85 | 0.075 | 21.216 | 3.539 |
| Foreign Exchange Effects | |||||
| Net Change in Cash | -2.702 | 3.526 | -12.94 | 15.47 | -0.383 |
| Cash Taxes Paid | 0.028 | 0.036 | 0.026 | ||
| Other Investing Cash Flow Items, Total | -20.515 | -16.087 | -3.906 | ||
| Issuance (Retirement) of Debt, Net | -0.006 | -0.005 | -0.005 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.508 | -13.592 | -10.346 | -6.896 | -3.622 |
| Cash From Operating Activities | -3.888 | -12.252 | -9.448 | -6.402 | -4.313 |
| Cash From Operating Activities | 0.006 | 0.024 | 0.018 | 0.012 | 0.006 |
| Non-Cash Items | 0.443 | 1.777 | 1.354 | 1.023 | 0.551 |
| Changes in Working Capital | -0.829 | -0.461 | -0.474 | -0.541 | -1.248 |
| Cash From Investing Activities | 2.214 | -20.537 | -11.848 | 0.98 | -0.009 |
| Capital Expenditures | 0 | -0.022 | -0.015 | -0.013 | -0.009 |
| Other Investing Cash Flow Items, Total | 2.214 | -20.515 | -11.833 | 0.993 | 0 |
| Cash From Financing Activities | -0.001 | 30.087 | 30.106 | 0.241 | 0.242 |
| Issuance (Retirement) of Stock, Net | 0 | 30.093 | 30.111 | 0.244 | 0.244 |
| Issuance (Retirement) of Debt, Net | -0.001 | -0.006 | -0.005 | -0.003 | -0.002 |
| Net Change in Cash | -1.675 | -2.702 | 8.81 | -5.181 | -4.08 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| EQT Partners AB | Private Equity | 10.8 | 2855847 | 304827 | 2022-07-08 | LOW |
| Trill AB,LLC. | Corporation | 9.6472 | 2551020 | 2551020 | 2021-09-28 | |
| Jacinto (Richard II) | Individual Investor | 9.4543 | 2500000 | 850947 | 2022-12-31 | LOW |
| Lytton (Laurence W) | Individual Investor | 4.0539 | 1071970 | -308296 | 2021-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.961 | 782989 | 349 | 2022-12-31 | LOW |
| Giuffre (Randall Michael) | Individual Investor | 1.4983 | 396184 | 35130 | 2023-01-03 | LOW |
| Omega Advisors, Inc. | Investment Advisor | 1.1345 | 300000 | 100000 | 2021-12-31 | LOW |
| Jacob Asset Management of New York, LLC | Investment Advisor | 0.8839 | 233730 | -4770 | 2022-12-31 | LOW |
| Pilnik (Richard D) | Individual Investor | 0.7937 | 209882 | 55555 | 2023-01-03 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6991 | 184870 | -349 | 2022-12-31 | LOW |
| Lynch (Timothy Patrick) | Individual Investor | 0.3792 | 100259 | -100000 | 2022-12-31 | LOW |
| Burroughs (Amy Louise) | Individual Investor | 0.2772 | 73288 | 17156 | 2023-01-03 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2723 | 72012 | 2814 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 66629 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2496 | 65997 | 1067 | 2022-12-31 | LOW |
| Pauls (Dietrich John) | Individual Investor | 0.211 | 55804 | 20000 | 2022-11-16 | |
| Morgan Stanley & Co. LLC | Research Firm | 0.1672 | 44201 | 2194 | 2022-12-31 | MED |
| Alcorn Harry W Jr | Individual Investor | 0.1663 | 43981 | 399 | 2022-03-22 | MED |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1612 | 42634 | 0 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.1483 | 39216 | 4304 | 2022-12-31 | HIGH |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
DiaMedica Therapeutics Inc. Company profile
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, DiaMedica Therapeutics Inc revenues was not reported. Net loss increased 11% to $13.6M. Higher net loss reflects General and administrative - Balancing increase of 23% to $3.8M (expense), Research and development - Balancing increase of 7% to $8.3M (expense), Governmental assistance research incen decrease from $205K (income) to $0K.
| Industry: | Bio Therapeutic Drugs |
301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US
Income Statement
- Annual
- Quarterly
News
PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com